Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Non-cash Items (2016 - 2017)

Corcept Therapeutics (CORT) has disclosed Non-cash Items for 6 consecutive years, with $263.1 million as the latest value for Q4 2017.

  • Quarterly Non-cash Items rose 310.36% to $263.1 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $263.1 million through Dec 2017, up 310.36% year-over-year, with the annual reading at $263.1 million for FY2017, 310.36% up from the prior year.
  • Non-cash Items hit $263.1 million in Q4 2017 for Corcept Therapeutics, up from $64.1 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $263.1 million in Q4 2017 to a low of $10.0 million in Q4 2013.
  • Historically, Non-cash Items has averaged $76.2 million across 5 years, with a median of $33.3 million in 2015.
  • Biggest five-year swings in Non-cash Items: increased 4.38% in 2014 and later skyrocketed 310.36% in 2017.
  • Year by year, Non-cash Items stood at $10.0 million in 2013, then grew by 4.38% to $10.5 million in 2014, then surged by 217.65% to $33.3 million in 2015, then skyrocketed by 92.45% to $64.1 million in 2016, then surged by 310.36% to $263.1 million in 2017.
  • Business Quant data shows Non-cash Items for CORT at $263.1 million in Q4 2017, $64.1 million in Q4 2016, and $33.3 million in Q4 2015.